Cephalon, Inc.

Sterling Winthrop Inc.

Other

Sanofi Winthrop Inc.

Matthew S Miller

John P Mallamo

William G Earley

Virendra Kumar

Chakrapani Subramanyam

Diane L DeHaven-Hudkins

Edward R Bacon

Sankar Chatterjee

Derek D Dunn

Jeffry L Vaught

Thomas E Scammell

John A Dority, Jr

Rabindranath Tripathy

Lisa D Aimone

Roland Ellwood Dolle

Robert L Hudkins

Ernest Knight, Jr

Irennegbe K Osifo

Lise Binderup

Todd L Graybill

Patricia C Contreras

Fredrik Bj&ouml;rkling

Ratan Venkatraman Bhat

Alex L Harris

Jill S Gregory

Thomas M Engber

Forrest A Haun

Michael S Saporito

Pawel Dobrzanski

Susan Carswell

Swing seat with cupholder

A magnetic license protection and tagging device includes a main body with at least one magnet. The main body has a first pocket for holding at least one of a license and a tag. The main body is foldable between an open position and a closed position. The at least one magnet is connected to the main body, and selectively militates against the main body moving from the closed position to the open position. The magnetic license protection and tagging device may be secured to a game animal by magnetic attraction. The magnetic license protection and tagging device is used to appropriately tag the game animal in compliance with hunting laws.

Magnetic license protection and tagging system

The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.

Substituted thioacetamides

Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.

Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue

Novel methods for the treatment and/or prevention of pain are presented. The methods may comprise administering to a subject in need thereof an effective amount of a stress-activated protein kinase inhibitor. Preferred compounds for use in the methods include fused pyrrolocarbazole compounds.

Methods for the treatment and prevention of pain

Modafinil is effective in improving symptoms of eating disorders or in stimulating appetite.

Compositions including modafinil for treatment of eating disorders and for appetite stimulation

The present invention is directed, inter alia, to methods of utilizing low calcemic vitamin D analogues. Particularly, the present invention is directed to using low calcemic vitamin D analogues to treat neurodegenerative diseases and disorders, to facilitate endogenous production of neurotrophic factors, to inhibit the degradation, dysfunction or loss of neural cells and/or to enhance the phenotype of neural cells or neuronal processes.

Vitamin D analogues and their neuronal effects

Disclosed herein are therapeutic methologies utilizing a ring substituted derivative of the indolocarbazole K-252a, the derivative represented by the formula:

Use of K-252a derivative

A method for determining a concentration of IGF-I that defines a therapeutically effective dose of IGF-I, i.e., a dose that will provide a therapeutic response in the treatment of neurological disorders for which IGF-I is utilized (including peripheral neuropathy, diabetic neuropathy, post-polio syndrome, small fiber neuropathy, ALS, and MS) is described. The method comprises determining whether a particular dose of IGF-I causes a 1.5 fold or greater increase in the homeostatic concentration of plasma IGFBP-2 in a mammal that has previously received a defined dose of IGF-I. The method of the invention can also be used to determine whether or not biological tolerance has developed to a particular dose of IGF-I.

Diagnostic uses of IGFBP-2

Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

Substituted 6,11-ethano-6,11-dihydrobenzo[B]quinolizinium salts and

Growing community of inventors

Newtown, PA, United States of America

Matthew S Miller